Literature DB >> 17217013

Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance.

A F Amer1, S A Zaki, A M Nagati, M A Darwish.   

Abstract

Hepatitis E virus has been implicated as a frequent cause of acute sporadic hepatitis among Egyptian children. Moreover, an extraordinarily high seroprevalence rate was previously reported in a semiurban Nile Delta population. A conspicuous feature of hepatitis E is the high morbidity and mortality it can cause among infected pregnant women. We therefore evaluated the prevalence of HEV antibodies in adolescent females using a solid-phase enzyme linked immunoassay based on two recombinant hepatitis E virus antigens. A high prevalence rate (38.9%) was found in 95 apparently healthy adolescent females. The mean age of the study subjects was 21.81 +/- 2.5 (SD) range 16-25 years. Eighty (84.2%) subjects resided in Alexandria, while 15 (15.8%) came from semiurban villages of Alexandria Governorate. An increased prevalence was noted with age, as anti-HEV antibodies were detected in 32.1% and 41.8% of study participants in the second and third decades of life, respectively. Similarly, those illiterate or having received less than primary education exhibited a higher HEV prevalence than those with higher education (46.3% vs 29.3%). The majority of subjects having serological evidence of HEV infection denied previous history of jaundice which shows that HEV infection was subclinical in those cases. Ten (55.6%) pregnant females participating in the study, as well as 48 (62.3%) non pregnant females lacked serological evidence of HEV infection; i.e., 60.01% (10 + 48 out of 95) of women in the childbearing age may be susceptible to infection. This report suggests that HEV is endemic in Alexandria, Egypt; the epidemiologic risk factors associated with HEV infection need further exploration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 17217013

Source DB:  PubMed          Journal:  J Egypt Public Health Assoc        ISSN: 0013-2446


  8 in total

1.  Hepatitis E: Epidemiology and prevention.

Authors:  Eyasu H Teshale; Dale J Hu
Journal:  World J Hepatol       Date:  2011-12-27

Review 2.  Host immune status and response to hepatitis E virus infection.

Authors:  Lisa J Krain; Kenrad E Nelson; Alain B Labrique
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 3.  Hepatitis E: Discovery, global impact, control and cure.

Authors:  Mohammad S Khuroo; Mehnaaz S Khuroo; Naira S Khuroo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 4.  A systematic review of the epidemiology of hepatitis E virus in Africa.

Authors:  Jong-Hoon Kim; Kenrad E Nelson; Ursula Panzner; Yogita Kasture; Alain B Labrique; Thomas F Wierzba
Journal:  BMC Infect Dis       Date:  2014-06-05       Impact factor: 3.090

5.  Epidemiology and associated risk factors of hepatitis e virus infection in plateau state, Nigeria.

Authors:  Surajudeen A Junaid; Samuel E Agina; Khadijah A Abubakar
Journal:  Virology (Auckl)       Date:  2014-05-27

6.  Seroprevalence of Dromedary Camel HEV in Domestic and Imported Camels from Saudi Arabia.

Authors:  Sherif Aly El-Kafrawy; Ahmed Mohamed Hassan; Mai Mohamed El-Daly; Ishtiaq Qadri; Ahmed Majdi Tolah; Tagreed Lafi Al-Subhi; Abdulrahman A Alzahrani; Ghaleb A Alsaaidi; Nabeela Al-Abdullah; Reham Mohammed Kaki; Tian-Cheng Li; Esam Ibraheem Azhar
Journal:  Viruses       Date:  2020-05-18       Impact factor: 5.048

7.  Setting a Course for Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review of Burden and Risk Factors.

Authors:  Aybüke Koyuncu; Daniel Mapemba; Iza Ciglenecki; Emily S Gurley; Andrew S Azman
Journal:  Open Forum Infect Dis       Date:  2021-04-13       Impact factor: 3.835

8.  Hepatitis E virus prevalence in Egyptian children with transfusion-dependent thalassemia.

Authors:  Doaa Abdelmawla; Dalia Moemen; Ahmad Darwish; Wafaa Mowafy
Journal:  Braz J Infect Dis       Date:  2019-02-28       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.